Thiraviam Pillai Rameshwari Ammal Kannan

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

Rengaswamy Sankaranarayanan, Priya R. Prabhu, Michael Pawlita et al. · The Lancet Oncology · 2015 · 244 citations · Full text

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study

Partha Basu, Sylla G. Malvi, Smita Joshi et al. · The Lancet Oncology · 2021 · 243 citations · Full text

Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination

Smita Joshi, Devasena Anantharaman, Richard Muwonge et al. · Vaccine · 2022 · 81 citations · Full text

Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study

Partha Basu, Richard Muwonge, Neerja Bhatla et al. · Papillomavirus Research · 2019 · 32 citations · Full text

Are two doses of human papillomavirus vaccine sufficient for girls aged 15–18 years? Results from a cohort study in India

Neerja Bhatla, Bhagwan M. Nene, Smita Joshi et al. · Papillomavirus Research · 2018 · 26 citations · Full text

Immunology, Are Two, Hpv Infection Outcomes +16